Message to Shareholders
We are driven by our I passion to reach every hospital with our quality products
Esteemed Shareholders, my colleagues on the Board, Good Morning to you all. A very warm
welcome to the 15th Annual General Meeting of ANG Lifesciences India Limited. We hope you
and your families are healthy and safe. The Annual Report for the year ended 31st March,
2021 along with notice of the meeting. Board's Report and the audited financial statements
of the Company have been circulated to you. With your permission, take them as read.
We meet once again through a virtual meeting, amid unprecedented times, where the world
is in the grip of second and a possible third wave of the pandemic. This has been a
challenging year for each one of us as we witnessed the heartbreaking impact of the
pandemic that devastated lives and livelihoods rendering a severe blow to societies and
economies. I wish to express solidarity with all those who lost their dear ones and, wish
speedy recovery to those who are infected or battling with the diseases.
I am delighted to write to you at the end of what has been a satisfying financial year
for the Company. Amid an uncertain global environment and challenging industry dynamics,
we have continued to grow. Despite challenges, the company delivered its best ever annual
profits this year which was made possible by its proactive approach in dealing with these
adversities by preplanning its procurement, logistics, and sales strategy. The company's
Bankers, many principals and clients provided tremendous support and the year showed us
all the strength of togetherness and unity. This encouraging performance has been
supported by our commitment to quality, adherence to compliance, manufacturing excellence
and strong supply chain capabilities.
Quality is the foundation on which ANG has built its market standing. Our products meet
relevant Indian and international pharmacopeial standard and statutory requirement.
Moreover, your company ensures that that all steps involved in design, development and
manufacturing of products lead to the intended level of quality performance in the market.
This commitment to quality requires us to ensure that our facility is equipped to provide
the right environment, our personnel are trained and quality conscious, our packaging
provides the requisite security and cosmetic appeal and our product provides complete
patient satisfaction. At ANG we have always believed that access to medicines at
affordable prices is a fundamental and basic human right, and a healthy community will
lead to a healthy and prosperous country. This is an opportune time for India to build a
robust Healthcare system where none should be denied medication.
We remain committed to investing in building new capacities and expanding our product
portfolio to deliver longterm, sustainable growth in our business. Your company has
successfully acquired Ind-swiff Ltd Unit No- 5 & 6 formulation manufacturing Oral
Solid Dosage plants at Rs 60 Crores on August 2021, which increased our overall capacity
to 20x with expected potential annual revenue of Rs 500 Crore to Rs 600 Crore.
Furthermore, Your Company is planning to commission M/s Star Biotech Pvt Ltd the
formulation production of Penicillin (dedicated) Plant. The Company began piloting trial
and expects to be in production at the end of Current FY. This plant is expected to
generate additional revenues of Rs 250 cr.
ANG is now a 15 year old company and the journey so far has been fraught with
unexpected obstacles and hurdles which we have resolutely overcome. Today our company has
grown and progressed to being one of the leading Pharmaceutical Companies in India. This
has been possible because of our compassionate approach to medicine and health care that
goes beyond the pursuit of profit and growth. The long process of hard work and
perseverance has been experienced by each and every one who has been part ot ANG
Lifesciences. throughout its victorious survival by 2026 company aspires to achieve a
turnover of worth Rs 2000 Crores. For this the Company may venture into backward and
forward integration by way of acquisition or fresh investment in CapEx.
Your company remains committed to the highest standards of Health, Safety, Security and
Environment or EHSS of its employees and communities while taking business decisions. The
Company has implemented internationally recognized ISO Standards in Environment and
Quality management systems. India is among the first countries to have made Corporate
Social Responsibility (CSR) mandatory following an amendment in the Companies Act, 2013.
At ANG Lifesciences India Limited, the Company has taken a number of initiatives to pay
back to society. During FY 2020-21, the Company has spent substantial amounton CSR
activities mainly on distribution of Nose mask. Sanitizers, etc.
The company believes that human resources are a critical factor for its growth. The
emphasis is on grooming in-house talent enabling them to take on larger responsibilities.
The company also has an excellent track record on industrial relations and no man-days
were lost on account of strike or dispute during the year.
As we celebrate our 15 years of existence of ANG, I take this opportunity to thank all
our colleagues, creditors, customers, bankers and various government Agencies and
investors. Currently we are doing our best to combat covid-19 and hope that the world will
overcome this pandemic and we will all emerge stronger as a community and we will continue
to contribute towards our mission of providing Quality and affordable medicines to.
Thank you.
Rajesh Gupta
Managing Director.